To differentiate mechanical from inflammatory lesion: 1-Site matters 2-Structural changes matter Denis Poddubnyy #RNL2023 ⁦@RheumNow⁩ https://t.co/iQ1gHPnkqO

Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/q3d6kNTVvo https://t.co/FBzZOMVlIK

• https://bit.ly/3JPrQMy

PAISLEY: Deucravacitinib in SLE #RNL2023 Year in Review DEUC: oral TYK2i P2, 48w DBRCT in active SLE Primary endpt SRI4 at w32 - meets endpt, no dose response Phase 3 study results needed, promising results but JAK studies failed for SLE @RheumNow https://t.co/kKAKHnnG8i

AAV outcomes in patients with diffuse alveolar hemorrhage , ⁦@RheumNow⁩ Kavanaugh #RNL2023 I think i will still use it in sever patients. https://t.co/AEDH4diDuU

#RNL2023 Year in Review New Drugs in Old Disease? GCA - Tocilizumab (GiACTA ), Secikinumab (TitAIN), Mavrilimumab (GM-CSFr mAb) PMR - Sarilumab (SAPHYR), TCZ (PMR-Spare, SEMAPHORE), Tofacitinib (EAST PMR) @RheumNow https://t.co/cY2HuaI6uM

An exciting year and time for GCA and PMR treatment! - Tocilizumab (IL-6i) - Secukinumab (IL-17i) - Sarilumab (IL-6i) - Mavrilimumab (GM-CSF receptor mAb) - Tofacitinib (JAKinib) @RheumNow #RNL2023 https://t.co/d0T2RAssFY

@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI

Extension PEXIVAS study in ANCA vasculitis pts with severe DAH - no significant effect of PLEX on mortality but do note numerical difference, favoring PLEX in severe DAH - note difference in curve @RheumNow #RNL2023 https://t.co/6ktb3Uakw9

Biosimilars are coming! Multiple adalimumab biosimilars this year - will we see a dramatic price difference? @RheumNow #RNL2023 https://t.co/8vdtXtEGOO

Biosimilars back on the radar for 2023. Expect to see 17 in rheum. #RNL2023 @RheumNow https://t.co/SNYNM8nmD2

Biosimilar to biosimilar switching of Infliximab , ⁦@RheumNow⁩ Kavanaugh #RNL2023 Communications is a key always. Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ

Will be begin using sputum instead of blood serologies to detect RA? - sputum seropositive CCP may be associated with development of clinical RA - 4 fold higher risk if (induced) sputum CCP+ @RheumNow #RNL2023 https://t.co/Z85GDwIyl8

#RNL2023 Year in Review Sputum antibody predicts future development of RA Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA) Strongest association with CCP IgA Supports pre-RA as mucosal disease @RheumNow https://t.co/Js4JPZiLDB

How does HCQ work @Lupusreference in #RNL2023 HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN HCQ works as base to increase lysosomal pH and affect cellular function @RheumNow https://t.co/RTEUF0cS0u

@Lupusreference in #RNL2023 HCQ and arrhythmia via QTc prolongation At normal doses, same as general population If on other QTc prolonging medications, a baseline EKG may be beneficial @RheumNow https://t.co/cAN2vBNa1t